Translational strategies involve RBM3-mediated therapies to reverse synaptic loss with extended immobility, temperature- or drug-triggered cold-shock protein induction, and metabolic modulators blocking excitotoxic signaling in ischemia or critical illness. Here, RBM3 is linked to ischemia.